200 related articles for article (PubMed ID: 31635547)
1. Angioedema late in the course of adjuvant nivolumab therapy for melanoma.
Ratra A; Dasanu CA
J Oncol Pharm Pract; 2020 Jun; 26(4):1019-1021. PubMed ID: 31635547
[TBL] [Abstract][Full Text] [Related]
2. Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma.
Dasanu CA
J Oncol Pharm Pract; 2019 Dec; 25(8):2052-2055. PubMed ID: 30782092
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab-induced hypothyoidism with consequent hypothyroid related myopathy.
Johnson ED; Kerrigan K; Butler K; Patel SB
J Oncol Pharm Pract; 2020 Jan; 26(1):224-227. PubMed ID: 30880569
[TBL] [Abstract][Full Text] [Related]
5. Bluish-gray fingernail discoloration due to the use of nivolumab.
Ocampo MM; Lerner J; Dasanu CA
J Oncol Pharm Pract; 2021 Mar; 27(2):457-459. PubMed ID: 32517636
[TBL] [Abstract][Full Text] [Related]
6. Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient.
Pillonel V; Dunet V; Hottinger AF; Berthod G; Schiappacasse L; Peters S; Michielin O; Aedo-Lopez V
J Immunother Cancer; 2019 Dec; 7(1):336. PubMed ID: 31791418
[TBL] [Abstract][Full Text] [Related]
7. Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti-PD-1 Therapy.
Parakh S; Cebon J; Klein O
Oncologist; 2018 Jul; 23(7):849-851. PubMed ID: 29666298
[TBL] [Abstract][Full Text] [Related]
8. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
Tan I; Malinzak M; Salama AKS
J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
[TBL] [Abstract][Full Text] [Related]
9. Dramatic effect of nivolumab against melanoma and immune-related liver toxicity: A detailed histopathological and immunohistochemical analysis of nivolumab-induced liver toxicity.
Namiki T; Nojima K; Chikazawa S; Iwamoto Y; Otsuki Y; Albusani H; Miura K; Kiyokawa Y; Asakage T; Yokozeki H
J Dermatol; 2019 May; 46(5):e182-e183. PubMed ID: 30474878
[No Abstract] [Full Text] [Related]
10. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
Larkin J; Minor D; D'Angelo S; Neyns B; Smylie M; Miller WH; Gutzmer R; Linette G; Chmielowski B; Lao CD; Lorigan P; Grossmann K; Hassel JC; Sznol M; Daud A; Sosman J; Khushalani N; Schadendorf D; Hoeller C; Walker D; Kong G; Horak C; Weber J
J Clin Oncol; 2018 Feb; 36(4):383-390. PubMed ID: 28671856
[TBL] [Abstract][Full Text] [Related]
11. Polymyalgia rheumatica in a melanoma patient 11 months after completion of immunotherapy with nivolumab.
Lobo Y; Good P; Murphy F
Cancer Rep (Hoboken); 2020 Jun; 3(3):e1244. PubMed ID: 32671986
[TBL] [Abstract][Full Text] [Related]
12. Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy.
Chin CK; Hall S; Green C; Van Hazel G; Spagnolo D; Cheah CY
Eur J Cancer; 2019 Jul; 115():84-87. PubMed ID: 31129384
[No Abstract] [Full Text] [Related]
13. 79-year Old Man on Nivolumab with Itchy Erythematous Patches.
Copur MS; Corey S
Oncology (Williston Park); 2020 Feb; 34(2):53-54. PubMed ID: 32645195
[TBL] [Abstract][Full Text] [Related]
14. Cycle-dependent eosinophilia due to adjuvant nivolumab for malignant melanoma.
Habibi S; Soliman A; Dasanu CA
J Oncol Pharm Pract; 2023 Jul; 29(5):1255-1258. PubMed ID: 36597613
[TBL] [Abstract][Full Text] [Related]
15. Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab.
Yamaguchi S; Morimoto R; Okumura T; Yamashita Y; Haga T; Kuwayama T; Yokoi T; Hiraiwa H; Kondo T; Sugiura Y; Watanabe N; Kano N; Kohno K; Fukaya K; Sawamura A; Yokota K; Ishii H; Nakaguro M; Akiyama M; Murohara T
Can J Cardiol; 2018 Jun; 34(6):812.e1-812.e3. PubMed ID: 29801747
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab exposure-response analysis for adjuvant treatment of melanoma supporting a change in posology.
Sanghavi K; Vuppala P; Ivaturi V; Hamuro L; Roy A; Suryawanshi S
CPT Pharmacometrics Syst Pharmacol; 2021 Jul; 10(7):748-759. PubMed ID: 33955714
[TBL] [Abstract][Full Text] [Related]
17. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
Yamauchi I; Yasoda A; Matsumoto S; Sakamori Y; Kim YH; Nomura M; Otsuka A; Yamasaki T; Saito R; Kitamura M; Kitawaki T; Hishizawa M; Kawaguchi-Sakita N; Fujii T; Taura D; Sone M; Inagaki N
PLoS One; 2019; 14(5):e0216954. PubMed ID: 31086392
[TBL] [Abstract][Full Text] [Related]
18. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab.
Hantel A; Gabster B; Cheng JX; Golomb H; Gajewski TF
J Immunother Cancer; 2018 Jul; 6(1):73. PubMed ID: 30012206
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab therapy before vemurafenib administration induces a severe skin rash.
Imafuku K; Yoshino K; Ymaguchi K; Tsuboi S; Ohara K; Hata H
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):e169-e171. PubMed ID: 27546003
[No Abstract] [Full Text] [Related]
20. Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient.
Teramoto Y; Nakamura Y; Asami Y; Imamura T; Takahira S; Nemoto M; Sakai G; Shimada A; Noda M; Yamamoto A
J Dermatol; 2017 May; 44(5):605-606. PubMed ID: 27334247
[No Abstract] [Full Text] [Related]
[Next] [New Search]
